Difference between revisions of "Malignant solid neoplasm, BRAF-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) (Created page with "<!--'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If th...") |
m |
||
| Line 11: | Line 11: | ||
'''Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.''' | '''Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.''' | ||
| + | =All lines of therapy= | ||
==Vemurafenib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ==Vemurafenib monotherapy {{#subobject:e0d17a|Regimen=1}}== | ||
===Regimen {{#subobject:392a4b|Variant=1}}=== | ===Regimen {{#subobject:392a4b|Variant=1}}=== | ||
Revision as of 02:35, 27 March 2018
2 regimens on this page
2 variants on this page
|
Note: this is a new type of page for HemOnc.org, as most other regimen pages are tissue-specific. We will collect published information from basket trials on these pages, as well as regimens that are FDA approved.
All lines of therapy
Vemurafenib monotherapy
Regimen
| Study | Evidence |
|---|---|
| Hyman et al. 2015 (VE-BASKET) | Phase II |
| Hainsworth et al. 2018 (MyPathway) | Phase IIa |
Eligibility criteria
- VE-BASKET: BRAF p.V600 mutations
- MyPathway: BRAF p.V600E mutation without coexisting KRAS mutations, or other BRAF mutations
Chemotherapy
- Vemurafenib (Zelboraf) 960 mg PO BID
Continued until progression or intolerance
References
- VE-BASKET: Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015 Aug 20;373(8):726-736. link to original article contains protocol link to PMC article PubMed
- MyPathway: Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536-542. Epub 2018 Jan 10. link to original article contains verified protocol PubMed